These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 25686137)

  • 1. Six- vs. eight-month anti-tuberculosis regimen for pulmonary tuberculosis under programme conditions.
    Ukwaja KN; Oshi SN; Alobu I; Oshi DC
    Int J Tuberc Lung Dis; 2015 Mar; 19(3):295-301, i-vii. PubMed ID: 25686137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tuberculosis treatment outcomes of six and eight month treatment regimens in districts of Southwestern Ethiopia: a comparative cross-sectional study.
    Asres A; Jerene D; Deressa W
    BMC Infect Dis; 2016 Nov; 16(1):653. PubMed ID: 27825309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results at 30 months of a randomised trial of two 8-month regimens for the treatment of tuberculosis.
    Nunn AJ; Jindani A; Enarson DA;
    Int J Tuberc Lung Dis; 2011 Jun; 15(6):741-5. PubMed ID: 21575292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clearance of theophylline is increased during the initial period of tuberculosis treatment.
    Ahn HC; Lee YC
    Int J Tuberc Lung Dis; 2003 Jun; 7(6):587-91. PubMed ID: 12797703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment options and outcomes of hospitalised tuberculosis patients: a nationwide study.
    Yamana H; Matsui H; Fushimi K; Yasunaga H
    Int J Tuberc Lung Dis; 2015 Jan; 19(1):120-6. PubMed ID: 25519801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance.
    Reves R; Heilig CM; Tapy JM; Bozeman L; Kyle RP; Hamilton CD; Bock N; Narita M; Wing D; Hershfield E; Goldberg SV;
    Int J Tuberc Lung Dis; 2014 May; 18(5):571-80. PubMed ID: 24903795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of a 12-month regimen for drug-resistant pulmonary tuberculosis.
    Pérez-Guzmán C; Vargas MH; Martínez-Rossier LA; Torres-Cruz A; Villarreal-Velarde H
    Int J Tuberc Lung Dis; 2002 Dec; 6(12):1102-9. PubMed ID: 12546119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children.
    Ramachandran G; Hemanth Kumar AK; Bhavani PK; Poorana Gangadevi N; Sekar L; Vijayasekaran D; Banu Rekha VV; Ramesh Kumar S; Ravichandran N; Mathevan G; Swaminathan S
    Int J Tuberc Lung Dis; 2013 Jun; 17(6):800-6. PubMed ID: 23676165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultrashort-course chemotherapy for culture-negative pulmonary tuberculosis--a qualified success.
    Cowie RL; Langton ME; Escreet BC
    S Afr Med J; 1985 Dec; 68(12):879-80. PubMed ID: 4071345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
    Mukherjee A; Velpandian T; Singla M; Kanhiya K; Kabra SK; Lodha R
    Int J Tuberc Lung Dis; 2016 May; 20(5):666-72. PubMed ID: 27084822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial.
    Jindani A; Nunn AJ; Enarson DA
    Lancet; 2004 Oct 2-8; 364(9441):1244-51. PubMed ID: 15464185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years].
    Brändli O; Haegi V; Villiger B; Bohn W; Baumann HR; Zäch R
    Schweiz Med Wochenschr; 1989 Mar; 119(10):299-305. PubMed ID: 2652281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
    Nolan CM; Goldberg SV
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Results of a therapeutic trial comparing a 6-month regimen to a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Final report: results 3 years after the onset of treatment].
    Berkani M; Chaulet P; Darbyshire JH; Nunn A; Fox W
    Rev Mal Respir; 1986; 3(2):73-85. PubMed ID: 3726263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of modified short course chemotherapy in active pulmonary tuberculosis patients with human immunodeficiency virus infection in University College Hospital, Ibadan, Nigeria--a preliminary report.
    Ige OM; Sogaolu OM; Odaibo GN; Olaleye OD
    Afr J Med Med Sci; 2004 Sep; 33(3):259-62. PubMed ID: 15819474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Split-drug regimens for the treatment of patients with sputum smear-positive pulmonary tuberculosis--a unique approach.
    Santha T; Rehman F; Mitchison DA; Sarma GR; Reetha AM; Prabhaker R;
    Trop Med Int Health; 2004 May; 9(5):551-8. PubMed ID: 15117298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modified short-course chemotherapy of pulmonary tuberculosis in Ibadan, Nigeria--a preliminary report.
    Ige OM; Bakare NA; Onadeko BO
    Afr J Med Med Sci; 2000 Mar; 29(1):51-3. PubMed ID: 11379469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled clinical trial comparing a 6-month and a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Algerian working group/British Medical Research Council cooperative study.
    Am Rev Respir Dis; 1984 Jun; 129(6):921-8. PubMed ID: 6375490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised Phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis.
    Jindani A; Borgulya G; de Patiño IW; Gonzales T; de Fernandes RA; Shrestha B; Atwine D; Bonnet M; Burgos M; Dubash F; Patel N; Checkley AM; Harrison TS; Mitchison D;
    Int J Tuberc Lung Dis; 2016 Jun; 20(6):832-8. PubMed ID: 27155189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.